From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

Recruiting N/A Interventional Study
Multiple Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
130 (estimated)
Sponsor
Nantes University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria : Common criteria for retrospective MS patients: * Patients aged 18 years or older * Clinical isolated syndrome (CIS) with or without dissemination in space * Patients affiliated to an appropriate health insurance Criteria for Aggressive MS group • Start of a 2nd line therapy …
Contacts

David LAPLAUD, PhD

33 2 40 16 52 00

david.laplaud@chu-nantes.fr

CONTACT